Profile data is unavailable for this security.
About the company
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
- Revenue in USD (TTM)69.10m
- Net income in USD-73.88m
- Incorporated2011
- Employees229.00
- LocationPersonalis Inc6600 Dumbarton CircleFREMONT 94555United StatesUSA
- Phone+1 (650) 752-1300
- Fax+1 (302) 531-3150
- Websitehttps://www.personalis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 684.69m | 111.00 | -- | 1.60 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 693.93m | 5.00 | -- | 120.30 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 0.00 | -71.11m | 701.26m | 45.00 | -- | 2.91 | -- | -- | -1.14 | -1.14 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -28.80 | -35.63 | -30.41 | -38.94 | -- | -- | -- | -314.68 | -- | -- | 0.00 | -- | 2,752.05 | -- | 90.01 | -- | -20.09 | -- |
| Annexon Inc | 0.00 | -208.88m | 706.83m | 99.00 | -- | 3.59 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| Kura Oncology Inc | 104.03m | -216.88m | 723.12m | 192.00 | -- | 3.04 | -- | 7.09 | -2.48 | -2.48 | 1.19 | 2.79 | 0.1844 | -- | -- | 541,817.70 | -38.45 | -26.38 | -44.88 | -28.06 | -- | -- | -208.48 | -1,266.72 | -- | -- | 0.0384 | -- | -- | -- | -13.99 | -- | -- | -- |
| Gyre Therapeutics Inc | 107.27m | 6.65m | 728.94m | 574.00 | 127.19 | 7.32 | 52.92 | 6.96 | 0.0646 | 0.0646 | 1.09 | 1.12 | 0.7537 | 0.6368 | 4.73 | 186,872.80 | 8.30 | -53.99 | 12.90 | -82.36 | 95.48 | 89.58 | 11.01 | -88.61 | 5.64 | -- | 0.00 | -- | -6.78 | -- | 113.00 | -- | 117.68 | -- |
| Personalis Inc | 69.10m | -73.88m | 729.08m | 229.00 | -- | 4.44 | -- | 11.01 | -0.8761 | -0.8761 | 0.8189 | 1.93 | 0.2863 | 7.71 | 4.96 | 301,759.80 | -30.61 | -29.82 | -36.03 | -34.69 | 26.67 | 28.44 | -106.92 | -105.71 | 4.69 | -- | 0.0133 | -- | 15.15 | 5.35 | 24.94 | -- | -28.17 | -- |
| Jade Biosciences Inc | 0.00 | -65.26m | 741.19m | 4.00 | -- | 2.53 | -- | -- | -11.45 | -11.45 | 0.00 | 5.50 | 0.00 | -- | -- | 0.00 | -44.48 | -47.29 | -50.06 | -50.63 | -- | -- | -- | -- | -- | -320.04 | 0.00 | -- | -- | -- | 7.80 | -- | -- | -- |
| Arvinas Inc | 312.30m | -58.50m | 748.21m | 430.00 | -- | 1.44 | -- | 2.35 | -0.8048 | -0.8048 | 4.30 | 7.97 | 0.3105 | -- | 22.63 | 726,279.10 | -5.82 | -20.58 | -7.36 | -25.05 | -- | -- | -18.73 | -211.50 | -- | -- | 0.0007 | -- | 235.54 | 43.71 | 45.85 | -- | -22.02 | -- |
| Kalvista Pharmaceuticals Inc | 15.12m | -210.31m | 753.65m | 270.00 | -- | 44.57 | -- | 50.12 | -3.95 | -3.95 | 0.2838 | 0.3363 | 0.0604 | -- | 1.51 | 55,992.59 | -84.00 | -49.86 | -97.02 | -54.21 | 87.95 | -- | -1,391.14 | -- | 7.21 | -82.77 | 0.9412 | -- | -- | -- | -44.85 | -- | 33.39 | -- |
| Maravai Lifesciences Holdings Inc | 192.28m | -121.24m | 756.89m | 550.00 | -- | 3.05 | -- | 3.90 | -0.8442 | -0.8442 | 1.34 | 0.961 | 0.1808 | 3.18 | 7.48 | 337,338.60 | -20.14 | 8.27 | -27.68 | 10.45 | 20.86 | 72.61 | -111.42 | 25.48 | 4.56 | -7.37 | 0.4288 | 0.00 | -10.30 | 12.61 | -21.69 | -- | 12.69 | -- |
| MiMedx Group Inc | 393.44m | 40.83m | 758.28m | 837.00 | 18.90 | 3.20 | 13.78 | 1.94 | 0.273 | 0.273 | 2.63 | 1.61 | 1.40 | 2.79 | 5.95 | 470,062.10 | 14.51 | 2.94 | 17.63 | 3.89 | 81.99 | 83.00 | 10.38 | 2.07 | 3.95 | -- | 0.0708 | -- | 8.52 | 3.12 | -24.73 | -- | -5.37 | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 765.45m | 44.00 | -- | 10.34 | -- | 54.91 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| Bicara Therapeutics Inc | 0.00 | -121.52m | 778.45m | 55.00 | -- | 1.91 | -- | -- | -5.03 | -5.03 | 0.00 | 7.38 | 0.00 | -- | -- | 0.00 | -25.61 | -- | -26.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.80 | -- | -- | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 781.32m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Janux Therapeutics Inc | 10.00m | -101.90m | 790.34m | 74.00 | -- | 0.8133 | -- | 79.46 | -1.67 | -1.67 | 0.1649 | 16.24 | 0.0116 | -- | -- | 135,135.10 | -11.85 | -13.75 | -12.17 | -14.23 | -- | -- | -1,018.95 | -743.21 | -- | -- | 0.00 | -- | 30.99 | -- | -18.36 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Personalis Inc's reporting currency: US Dollar USD
42.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2025 | 10.78m | 12.16% |
| ARK Investment Management LLCas of 31 Dec 2025 | 7.88m | 8.89% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.32m | 4.87% |
| abrdn, Inc.as of 31 Dec 2025 | 3.25m | 3.67% |
| AIGH Capital Management LLCas of 31 Dec 2025 | 2.90m | 3.27% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.88m | 3.24% |
| Kennedy Capital Management LLCas of 31 Dec 2025 | 1.71m | 1.93% |
| Blue Water Life Science Advisors LPas of 30 Sep 2025 | 1.68m | 1.89% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.30m | 1.46% |
| Millennium Management LLCas of 30 Sep 2025 | 1.21m | 1.37% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
